Disclaimer

Das alfapump®-System ist derzeit weder in den Vereinigten Staaten noch in Kanada zugelassen. In den Vereinigten Staaten und Kanada befindet sich das alfapump®-System gegenwärtig in der klinischen Prüfung (POSEIDON-Studie) und wird bei erwachsenen Patienten mit refraktärem oder rezidivierendem Aszites aufgrund von Zirrhose untersucht. Weitere Informationen zur klinischen Studie POSEIDON finden Sie unter www.poseidonstudy.com.
Die DSR®-Therapie befindet sich aktuell in der Entwicklung, und es ist zu beachten, dass alle Aussagen in Bezug auf Sicherheit und Wirksamkeit auf laufenden präklinischen und klinischen Untersuchungen beruhen, die noch nicht abgeschlossen sind.
Die DSR®-Therapie ist derzeit in den Vereinigten Staaten oder Kanada nicht zur klinischen Forschung zugelassen. Es gibt keinen Zusammenhang zwischen der DSR®-Therapie und laufenden Untersuchungen mit dem alfapump®-System in Europa.

Pressemeldungen

Transparency Notifications from Shareholders

Regulated information 23 February 2021, 06:00 pm CET Ghent, BELGIUM – 23 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today in accordance with Article 14 of the Belgian Act of...

SEQUANA MEDICAL’S NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASE REGULATED INFORMATION 16 February 2021, 07:00 am CET   Ghent, Belgium, 16 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act...

Sequana Medical announces February-March 2021 Investor Conference Schedule

Ghent, BELGIUM – 15 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in the following upcoming virtual investor conferences. BTIG Virtual MedTech, Digital Health, Life Science &...

Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe

Ghent, BELGIUM – 4 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents  for the alfapump DSR (Direct Sodium Removal) programme in the U.S. and European Union. U.S. patent number 10,898,631...

Sequana Medical announces January 2021 Investor Conference Schedule

Ghent, BELGIUM – 17 December 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference....

Sequana Medical to host KOL event on “The challenge of diuretic resistance in the management of heart failure patients and the potential for alfapump® DSR therapy”  

Live webcast with Dr. Jeffrey Testani on 11 December 2020 at 03:00 pm CET / 09:00 am EST Ghent, BELGIUM – 07 December 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that it will hold a key...

Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)

REGULATED INFORMATION – INSIDE INFORMATION 19 November 2020, 08:00 am CET   Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baseline Indication of rapid and persistent clinically relevant improvement in patients’ quality of life Safety profile in line with expectations Interim data of the...

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

Ghent, BELGIUM – 12 November 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020....

Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 22 October 2020, 07:00am CET   RED DESERT: Results from first five patients indicate repeated dose alfapump DSR therapy to be safe and effective Interim data support DSR hypothesis: kidneys eliminate free water to maintain patients’ serum sodium levels No patients required loop diuretic therapy during the six-week...

Sequana Medical appoints two additional experts as Heart Failure Scientific Advisors

Dr. Felker and Dr. Udelson join current advisors to support the development of alfapump® DSR for the management of fluid overload in patients with heart failure   Ghent, BELGIUM – 15 October 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
1 2 3 6

Abonnieren Sie unsere Pressemitteilungen

I agree to the Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close